Cells · 6 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This preclinical mouse study used a laser-induced retinal injury model to test if the antifibrotic drug pirfenidone could reduce scarring. The study found that pirfenidone treatment significantly reduced lesion size and increased cell count in the outer nuclear layer at specific time points.
The central result was that PFD treatment, initiated 14 days post-laser, led to a significant reduction in lesion volume on days 21 and 42 compared to untreated controls, and a significant increase in nuclei in the outer nuclear layer (ONL) at day 35. The analysis of ECM components revealed complex, time-dependent changes in collagen and fibronectin expression following injury. Limitations include the use of a mouse model, the specific injury mechanism (laser), and the observation that lesion size increased again after PFD treatment was stopped.
